Bellicum Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLCM research report →
About the company
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets.
- CEO
- David M. Maggio
- IPO
- 2014
- Employees
- 13
- HQ
- Houston, TX, US
Price Chart
- Market Cap
- $778.33K
- P/E
- -0.09
- P/S
- 0.52
- P/B
- 1.14
- EV/EBITDA
- 0.84
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1798.73%
- Net Margin
- -1664.87%
- ROE
- -189.12%
- ROIC
- -134.56%
- Revenue
- $1.50M · -75.81%
- Net Income
- $-24,973,000 · -160.73%
- EPS
- $-0.81 · 2.41%
- Op Income
- $-26,981,000
- FCF YoY
- -11.64%
- 52W High
- $1.31
- 52W Low
- $0.06
- 50D MA
- $0.11
- 200D MA
- $0.26
- Beta
- 1.38
- Avg Volume
- 28.58K
Get TickerSpark's AI analysis on BLCM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 22, 23 | BAKER BROS. ADVISORS LP | other | 1,941,607 |
| Nov 22, 23 | BAKER BROS. ADVISORS LP | other | 1,941,607 |
| Nov 22, 23 | BAKER BROS. ADVISORS LP | other | 174,742 |
| Nov 22, 23 | BAKER BROS. ADVISORS LP | other | 174,742 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 0 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 0 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 4,108,140 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 4,108,140 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 1,531,902 |
| May 5, 23 | BAKER BROS. ADVISORS LP | other | 1,615,945 |
Our BLCM coverage
Recent articles, reports, and earnings notes.
No research on BLCM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLCM report →Similar companies
Peers in the same neighborhood.